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Abstract
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells known to modulate the immune system and
to promote hematopoiesis. These dual effects make MSCs attractive for use as cellular therapy in hematopoietic
cell transplantation (HCT). MSCs can be used peri-HCT or pre-engraftment to modulate immune reconstitution,
promoting hematopoietic stem cell (HSC) engraftment and/or preventing graft-versus-host disease (GVHD).
Pre-clinical studies have demonstrated that MSCs can potentiate HSC engraftment and prevent GVHD in a variety
of animal models. Clinical trials have been small and largely non-randomized but have established safety and early
evidence of efficacy, supporting the need for larger randomized trials.
Background
Mesenchymal Stromal Cells in Hematopoietic Cell
Transplantation
Mesenchymal stromal cells (MSCs) are multipotent
progenitors that promote hematopoiesis and have
unique immunoregulatory properties, making them
attractive for use as cell-based therapy during and post
hematopoietic cell transplantation (HCT). They co-
localize with hematopoietic stem cells (HSCs) in the
normal bone marrow (BM) niche, producing factors
that promote and recruit HSCs and regulate their
function [1]. MSCs also regulate both innate and adap-
tive immune responses through effects on various im-
mune cells, particularly T cells and antigen-presenting
cells [2–4]. Specifically, they down-regulate immune re-
sponses by promoting regulatory T cells and inhibiting
cytotoxic T cell proliferation. Human MSCs have been
shown to function via IFN-γ-dependent upregulation of
indoleamine 2,3-dioxygenase (IDO), whereas inducible
nitric oxide species are important for the function of
MSCs from mice and other species [5, 6].
The surge in pre-clinical and clinical studies of MSCs
led the International Society for Cellular Therapy to
define minimal phenotypic and functional criteria for
MSCs in 2006 [7, 8]. Numerous clinical trials have dem-
onstrated the feasibility of ex vivo expansion of MSCs
and the safety of MSC infusion. There are currently
more than two-hundred and fifty open MSC trials
(https://www.clinicaltrials.gov/). In HCT, the use of
MSCs can be broadly categorized into early (peri-trans-
plant or early post-transplant) versus late administration
(late post-transplant; Fig. 1). MSCs have been given in
the late post-transplant period primarily as treatment for
graft-versus-host disease (GVHD), and there are cur-
rently over twenty open studies for this indication regis-
tered at https://www.clinicaltrials.gov/. The use of MSCs
to treat GVHD has been reviewed extensively elsewhere
[9, 10]. Studies to date show promise in certain subsets
of patients, specifically in pediatric rather than adult pa-
tients and in the treatment of liver and gut rather than
skin GVHD. This review will focus exclusively on the
early administration of MSCs in HCT to modulate im-
mune reconstitution and engraftment.
Early Administration of MSCs in HCT
Based upon their dual role in supporting hematopoiesis
and modulating immunity, MSCs have been studied in
the peri- and early post-transplant period to promote
engraftment and immune reconstitution. Given known
MSC immunomodulatory capacity and pre-clinic studies
of MSCs given peri-HCT, MSCs likely promote engraft-
ment through the inhibition of recipient immune cells
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that remain following transplant conditioning and
through the promotion of other immunomodulatory
cell populations, such as regulatory T cells (Fig. 2a)
[3, 5, 11, 12]. As T lymphocytes and natural killer
cells are a primary driver of graft rejection, it is likely
that MSCs impact on these cell populations, both
through cell-cell interactions and through secretion of
soluble factors [3, 5, 11, 12]. Additionally, it is prob-
able that MSCs also enhance engraftment through
interaction with donor CD34+ hematopoietic stem
cells (HSCs), potentially by directing HSCs to the
bone marrow niche or increasing their survival
(Fig. 2b) [13–16]. This MSC/stem cell interaction may
occur either before stem cells reach the bone marrow
niche or in the niche itself, although the majority of
clinical studies fail to show engraftment of infused
MSCs, making it more likely to occur outside of the
marrow.
Engraftment of HSCs is a considerable barrier to suc-
cessful transplant, particularly in HCT for non-malignant
diseases (NMD). Graft failure is predominantly immune-
mediated, wherein recipient T cells play a dominant role
in rejecting donor hematopoietic cells [17, 18]. The risk of
graft failure therefore increases with the degree of human
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Fig. 1 Early (peri- or post-transplant) versus late administration of MSCs in HCT. MSCs can be administered to HCT patients in either early or late
time periods. The early time period constitutes either peri- or early post-transplant, which includes the use of MSCs to promote engraftment or to
prevent GVHD. MSCs can potentiate engraftment via direct infusion peri-transplant or via ex-vivo co-culture with HSCs. The late time period constitutes






















Fig. 2 Potential mechanisms of MSC potentiation of engraftment. Pre-clinical studies (in vivo small animal and in vitro with human MSCs) suggest
that MSCs function via interaction with other immune cells (Fig. 2a) and with donor CD34+ hematopoietic stem cells (HSCs; Fig. 2b). MSCs may inhibit
activated residual recipient immune cells, in particular T lymphocytes and natural killer cells which are known to be drivers of HCT rejection, and/or
may promote other regulatory immune cell populations, such as regulatory T cells. As shown in Fig. 2a, some potential mechanisms of this former
effect are demonstrated, including cell-cell interaction (such as through B7H1 or B7DC/PD1 on MSCs) or secretion of small molecules (such as PGE-2
through COX2, kynurenine through IDO, and IL-10). MSC likely interact with HSCs through cell-cell interactions, which more likely occur before HSCs
reach the bone marrow niche and may lead to HSCs being directed to the niche and/or to increased HSC survival (Fig. 2b)
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leukocyte antigen (HLA) mismatch, intensity of pre-
transplant conditioning, and ex-vivo graft T cell
depletion (TCD) [17]. Engraftment following umbilical
cord blood transplantation (CBT) has been particu-
larly challenging in patients with NMD, which can be
partly, but not completely overcome with increasing
cell dose [19, 20].
MSCs to Promote Engraftment in Experimental HCT Models
MSCs given in the peri-transplant period have been
shown to promote engraftment across a variety of pre-
clinical models and using different MSC sources
(Table 1). The majority of murine studies have utilized a
NOD/SCID model giving sub-lethal doses of radiation
prior to transplantation. MSC isolated from random
donor human fetal lung [21, 22], fetal BM [22], adult
BM [22], and placenta [13] enhance engraftment of a
single human CD34+ CB, although results were not sta-
tistically significant using placental MSCs. Both placental
[13] and BM [23] MSCs enhance double CB engraftment
in the NOD/SCID mouse model. Third-party human
BM MSCs also increase the engraftment of a double CB
compared to single CB with MSC co-transplantation
(including with 5 locus mismatch) and to double CB
alone [23]. Both human placental and BM MSCs also
significantly decrease single cord dominance in this
model [13, 23].
Different subsets of MSCs have been evaluated to
potentiate engraftment in murine models. The infu-
sion of CD271+ MSCs, a potential marker of precur-
sor MSCs, isolated from human BM has been
compared to the infusion of standard MSC (PA-MSC)
for engraftment of human CD133+ peripheral blood
(PB) cells into NOD/SCID mice (Table 1) [24]. In this
study, CD271+ MSCs contained the entire colony-
forming unit (CFU)-fibroblast activity (with none in
CD271− fraction) and had 1–3 fold higher proliferation
compared to standard MSCs (so-called plastic adher-
ent or PA-MSCs) [24]. While both MSC subsets in-
creased engraftment, CD271+ MSCs resulted in
greater CD45+ donor cell engraftment than PA-MSC
[24]. STRO-1, which is expressed by adult BM fibro-
blast colony-forming units, has been thought to de-
fine a precursor subset of MSCs [25]. Similar to
studies of CD271, both STRO-1+ and STRO-1− MSCs
have been shown to increase BM, PB and spleen en-
graftment of human CB cells in this model, although
STRO-1− MSCs are superior in this effect while
STRO-1+ MSCs have greater migratory potential [25].
MSC donor source and dose may also impact the ef-
fect of MSC on engraftment. In two separate murine
Table 1 Use of MSCs to promote engraftment in murine models
HSC source Model Conditioning MSC source MSC dose Outcome Ref
Human UCB CD34+
cells
NOD/SCID mice 3.5 Gy Human fetal lung 1 × 106 3-4 fold increased donor CD45+ (lymphoid &




NOD/SCID mice 3.5 Gy Fetal lung, liver, or
BM or adult BM
1 × 106 Fetal lung & BM & adult BM MSCs increased




cells (single vs double)
NOD/SCID mice 3.25 Gy Human placenta 4 × 104 Increased engraftment (total & CD34+), no




cells (single vs double)









7 × 105 (1:8)
Increased engraftment (CD45+, CD33+, CD19+),
no effect on CD41a+, CD3+, CD56+ Increased
engraftment (CD271+ > PA-MSC), comparable
increase CD33+ & CD41a+, CD271+ increase




NOD/SCID mice 3.5 Gy Human BM
(STRO-1+ or
STRO-1−)
1 × 106 STRO-1− MSC increased engraftment of donor
CD45+ in BM, PB, or spleen more than STRO-1+,








5-6 Gy Syngeneic, allogeneic,
or 3rd party BM
0.25 ×
106; days 0, 4,
7, 10, 14
Syngenic MSCs increase engraftment, donor





NOD/SCID mice 3 Gy Autologous (PB) or
allogeneic (BM), human
1 × 106 Increased donor CD45+ with either MSC source,
allogeneic MSCs increased myeloid engraftment
and megakaryocytopoiesis
15
MSCs indicates mesenchymal stromal cells, HSC hematopoietic stem cell, UCB umbilical cord blood, NOD/SCID nonobese diabetic/severe combined
immunodeficiency, Gy gray, BM bone marrow, NR not reported, TCD T cell depleted, PB peripheral blood, PA-MSC plastic-adherent MSC, NK natural killer
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models (multiple minor mismatched and MHC mis-
matched), syngeneic BM MSCs significantly increase en-
graftment, allogeneic BM MSCs significantly decrease
engraftment, and third-party BM MSCs have no effect
[14]. In contrast, in a NOD/SCID model autologous or
allogeneic MSCs comparably increase BM myeloid en-
graftment of human CD45+ cells [15]. This suggests that
at least in a murine model of HCT, MSCs are not immu-
noprivileged, and that the donor source of MSCs can
lead to profound differences in engraftment depending
on the transplant model. Further, MSCs appear to have a
greater impact on engraftment at lower HSC doses. Fetal
lung MSCs increase the percent of human CD45+ cells
engrafting in the BM by 3–4 fold, which was most pro-
nounced at lower CD34+ cell doses (0.03-0.1 × 106) [21].
Studies utilizing allogeneic MSCs found that promotion
of myeloid engraftment was greatest with HSC doses <1
× 106 giving further indication for a threshold level of the
MSC effect on engraftment [15].
The capacity of MSCs to enhance engraftment has also
been studied in large animal models (Table 2). In an in-
utero human-sheep xenograft model, co-transplantation
of human BM MSCs increased PB and BM engraftment
of human CD34+ BM cells [16]. Donor source did not
impact the ability of MSCs to promote graft acceptance,
as both allogeneic and autologous MSCs had similar ef-
fects [16]. MSCs had no effect in two canine models of
HCT using different MSC and HSC donor sources [26,
27]. Third-party MSCs (either from primary culture or
an immortalized clonal population) had no impact on
the engraftment of canine haploidentical BM cells fol-
lowing total body irradiation (TBI) when compared to
BM cells alone, with half of animals rejecting grafts and
half developing fatal acute GVHD [26]. Three dosing
schedules were studied, but the sample size in each was
too small to make inferences about dosing [26]. The
authors hypothesize that post-transplant immunosup-
pression may be required in this model in order to see
an impact of MSCs [26]. Donor-derived BM MSCs also
had no impact on engraftment in a canine dog leukocyte
antigen-identical transplant model using non-
myeloablative conditioning (1 Gray), a model in which co-
stimulation (CTLA4) blockade or anti-CD154 has been
successful [27]. Failure of MSCs in these canine models
may be attributed to numerous reasons, including source
of MSCs, intensity of conditioning, absence of post-
transplant immunosuppression, and/or the dosing sched-
ule of MSCs. Finally, MSCs have been studied in a nonhu-
man primate model of autologous CD34+ intra-BM
transplant, wherein autologous BM MSCs increased the
percent of donor CFUs found in recipient BM, although
the primates were not followed long term [28].
Clinical Trials of MSCs to Promote Engraftment
As summarized in Table 3, a number of clinical trials
have been published demonstrating the use of MSCs to
promote HSC engraftment. These trials have all utilized
a variety of MSC and HSC donor sources and a variety
of MSC culture conditions making it difficult to directly
compare studies. They are exclusively phase I and II
trials that provide evidence of safety and supportive evi-
dence for future larger phase III trials. These studies
largely use allogeneic or MHC unmatched random
donor third-party MSCs in an allogeneic HCT setting,
although one of the earliest studies utilized autologous
MSCs to support engraftment of autologous PB HSCs
following high dose chemotherapy for breast cancer
[29]. Although this study found no difference in
Table 2 Use of MSCs to promote engraftment in large animal models
HSC source Model Conditioning;
Immune
suppression





None; n/a Human autologous
& allogeneic BM
5 × 104 - 7.5 × 105 Increased engraftment










3 dosing schedules: 30 × 106/kg
3×/wk ×1 wk, then 2×/wk;
15 × 106/kg 5×/wk; 1 × 106/kg
3×/wk
No effect; 50 % graft





Canine 1 Gy; MMF
and CSA
Donor-derived BM 1.2 - 1.8 × 106/kg day 0, 1.1 -
1.3 × 106/kg day 35
No effect, uniform graft
rejection at median of











Autologous BM NR 1.6-6 fold increase in donor
CFUs in BM
28
MSCs indicates mesechymal stromal cells, HSC hematopoietic stem cells, BM bone marrow, PB peripheral blood, Gy gray, Bu busulfan, NR not reported, CFUs
colony-forming units, wk week, GVHD graft-versus-host disease, DLA dog leukocyte antigen, MMF mycophenolate mofetil, CSA cyclosporine
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Table 3 Clinical trials of MSCs to promote engraftment
Patient population HSC source Conditioning; Immune
suppression
MSC source MSC dose MSC culture conditions Outcome Ref
Adult breast cancer, n = 28 Autologous PB Cy/Thio/Carbo; n/a Autologous BM Day 0 − +1: ≥ 1 ×
106/kg
FBS; Fresh or cryopreserved
(n = 8); Passages NR
Engraftment of neutrophils 8 d &
platelets 8.5 d; No difference
compared to historical control
group
29
Pediatric HR acute leukemia,
n = 8
UCB Cy/TBI or Bu/Mel




Day 0: 2.1 × 106/
kg; Day 21: 1 × 106/
kg, n = 3
PlasmaLyte A, 5 % HSA;
Cryopreserved; P1-P4
100 % donor chimerism (d 21),
engraftment of neutrophils 19 d
& platelets 53 d; 14 % gr II-IV
aGVHD, no cGVHD; No difference
compared to historical control
group
30
Pediatric leukemia or HLH,
n = 13
UCB TBI or chemotherapy-
based; CSA +/− steroids
Haplo BM
(parent)
Day 0: 1.9 × 106/kg FBS; Fresh or cryopreserved;
P2-P3
85 % donor engraftment,
engraftment of neutrophils 30
d & platelets 32 d; 31 % gr II-IV
aGVHD (0 % gr III-IV), 0 % cGVHD;
↓ gr III-IV aGVHD (p = 0.05),
otherwise no difference compared
to historical control group
31
Pediatric hemoglobinopathy,
SCD (n = 4) or thalassemia
major (n = 2)





Haplo (1) or third-
party (5) BM
Day 0: 2 × 106/kg;
Day 2: 2 × 106/kg
FBS; Cryopreserved; Passages
NR
2 with primary graft failure & 2












n = 7 haplo)
Day 0: 1.2 × 106/kg FBS; Cryopreserved; P1-P3 100 % donor engraftment (51 d),
engraftment of neutrophils 12 d
& platelets 44 d; 44 % gr II-IV
aGVHD (0 % gr III-IV), 13 % cGVHD;
No difference compared to
concurrent control group
33
Pediatric & adult patients,
leukemia (n = 3) or NMD
(n = 4), indication graft failure
in 3
MSD BM (1) or PB
(2); UD BM (1), PB
(2), or UCB (1)
Myeloablative (3) or RI
(4) +/− ATG (6); CSA
+/− MTX (4)
Haplo (4) or MSD
(3) BM
Day 0: 1 × 106/kg FBS; Fresh vs cryopreserved
NR; P2-P3
100 % donor engraftment,
engraftment of neutrophils 12 d &
platelets 12 d; 29 % gr II-IV aGVHD




malignancy, n = 46
MSD BM or PB Myeloablative; CSA &
MTX





Engraftment of neutrophils 14 d &
platelets 20 d; 28 % gr II-IV aGVHD,










based +/− ATG (haplo);
CSA +/− MTX (MSD)
Haplo or MSD BM
(same as HSC)
1 × 106/kg, day
+159.5 (median)
Ultroser G serum substitute;
Fresh vs cryopreserved NR;
P2-P3
No response in 4 patients; 2 patients
in CR1 with prompt neutrophil
recovery (d 5 & 15) and platelet









based (64 %); NR
Haplo BM (same
as HSC)
Day 0: 1.6 ×106/kg
(mean)
FBS; Fresh or cryopreserved;
P1-P3
100 % donor engraftment,
engraftment of neutrophils 12 d &
platelets 10 d (mean);
38 % gr II-IV aGVHD (0 % gr III-IV), 7 %














Table 3 Clinical trials of MSCs to promote engraftment (Continued)
leukocyte recovery (p = 0.009), otherwise
no difference compared to historical control
group
Adult & young adult patients,
hematologic malignancy,
n = 30
MSD PB or BM Cy/TBI or Bu/Cy; CSA
& MTX; open-label
randomization to
control or MSC group,
n = 15 per group
MSD BM Day 0: 3.3 × 105/kg FBS; Fresh vs cryopreserved
NR; Passages NR
5 patients in MSC group did not receive
MSCs due to failed expansion; No
difference in time to neutrophil & platelet
engraftment; decreased incidence aGVHD
(11.1 vs 53.3 %) & cGVHD (14.3 vs 28.6 %);
comparable rates of infection; increased
relapse (60 vs 20 %) and decreased DFS
(30 vs 66.7 %) and OS (40 vs 66.7 %), no
p-values reported
38
MSCs indicates mesenchymal stromal cells, HSC hematopoietic stem cell, PB peripheral blood, Cy cytoxan, Thio thiotepa, Carbo carboplatin, n/a not
applicable, BM bone marrow, FBS fetal bovine serum, NR not reported, d days, MSD matched sibling donor, CSA cyclosporine, MTX methotrexate, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host
disease, NMD non-malignant disease, haplo haploidentical, TCD T cell depleted, TBI total body irradiation, DFS disease-free survival, OS overall survival, HR high-risk, UCB umbilical cord blood, eATG equine anti-













neutrophil and platelet engraftment compared to a his-
torical control group, it is the only study to use autolo-
gous MSCs and the only following autologous HCT
[29]. Two patients initially enrolled on study did not re-
ceive their autologous MSCs due to persistence of BM
involvement by breast cancer, highlighting a potential
concern of using autologous MSCs in the malignant dis-
ease setting [29].
Several clinical trials have evaluated the use of peri-
transplant MSCs following CBT using third-party or
haploidentical MSCs (Table 3). Following infusion of
haploidentical MSCs, pediatric patients with high-risk
acute leukemia had engraftment and rates of GVHD
comparable to historical controls; all 8 patients engrafted
with a low rate of aGVHD [30]. A similar study utilized
haploidentical MSCs in pediatric patients with
hematologic malignancies and hemophagocytic lympho-
histiocytosis [31]. Compared to a historical control
group, there were comparable rates of engraftment, al-
though patients receiving MSCs had significantly less
grade III-IV aGVHD [31]. Statistically more patients in
the historical control group received granulocyte-colony
stimulating factor compared to patients in the MSC
group, which may have masked a difference in neutro-
phil engraftment [31]. The majority of study patients
also received more than the minimum CD34+ cell dose,
which the authors suggest may have impacted the ability
to demonstrate the effect of MSCs in potentiating en-
graftment [31]. Interestingly, no patients in either of
these studies developed cGVHD [30, 31]. A third study
in pediatric patients with hemoglobinopathies utilized
MSCs from third-party or haploidentical donors to po-
tentiate CB engraftment; two patients died from
transplant-related complications prior to achieving en-
graftment and the remaining two patients had graft re-
jection with auto-reconstitution [32]. This study was
halted prematurely and highlights the significant engraft-
ment barrier in patients with hemoglobinopathies fol-
lowing CBT [32]. Finally, a study of adult patients with
high-risk hematologic malignancies found comparable
rates of engraftment in patients receiving donor-derived
(mostly haploidentical) MSCs to that of a concurrent con-
trol group [33]. Both groups of patients received CB con-
current with third-party TCD PB HSCs [33]. All patients
receiving MSCs had rapid donor engraftment with a low
incidence of cGVHD and no grade III-IV aGVHD [33].
MSCs have been utilized in the transplant of BM or
PB HSCs from sibling, unrelated, and haploidentical do-
nors (Table 3). The majority of these studies occurred in
relatively homogenous populations of patients and used
homogenous MSC and HSC sources; Le Blanc et al.
[34], for example, infused haploidentical or matched-
sibling donor (MSD) MSCs into a heterogeneous patient
population making it difficult to garner much from this
trial aside from safety. This trial included pediatric and
adult patients with leukemia or NMD, conditioned pa-
tients with myeloablative or reduced-intensity regimens,
and utilized HSCs from MSD BM or PB, MUD BM or
PB, or CB [34]. Two studies evaluated MSCs in adult pa-
tients with hematologic malignancies, although the lack
of even a historical comparison group makes both stud-
ies difficult to interpret [35, 36]. MSD BM or PB engraft-
ment was rapid in patients who received peri-transplant
MSCs from their MSD [35]. The second study employed
MSCs in the setting of poor hematological recovery (full
donor chimerism with <10 % cellularity in BM) [36].
The six patients received donor-derived MSCs a median
of 160 days post haploidentical or MSD HCT, with two
patients having prompt neutrophil and platelet engraft-
ment [36]. An additional study infused haploidentical
MSCs into pediatric patients with primarily hematologic
malignancies to potentiate haploidentical HSC engraft-
ment [37]. Patients receiving MSCs had significantly fas-
ter leukocyte and reticulocyte recovery when compared
to a historical control group [37]. Although there were
no significant differences in rates of GVHD, it is notable
that there was no grade III-IV aGVHD in the MSC
group [37].
In the only randomized trial of MSCs given peri-HCT
to date, primarily adult patients with hematologic malig-
nancies undergoing MSD HCT were randomized to
standard GVHD prophylaxis (cyclosporine and metho-
trexate) or standard GVHD prophylaxis plus MSCs from
their MSD (Table 3) [38]. There were significant difficul-
ties in expanding MSCs; five patients randomized to re-
ceive MSCs did not receive any and the median dose of
MSCs was low at 3.3 × 105/kg [38]. The authors report
significantly decreased rates of acute and chronic GVHD
in the MSC group and significantly increased rates of re-
lapse, leading to decreased event-free survival and
overall survival, although no statistical analyses are
reported [38]. Data analysis was also not performed
using an intent-to-treat analysis, therefore the effect of
randomization was not preserved and significant differ-
ences between the two groups may have occurred lead-
ing to confounding of results.
In addition to being given early in HCT to support
HSC engraftment, MSCs have been employed to pro-
mote ex vivo expansion of HSCs. In an elegant study by
de Lima et al. [39], adult patients with hematologic ma-
lignancies receiving double CBT had the smaller CB ex-
panded in ex-vivo co-culture with MSCs then infused on
day 0 following receipt of the unmanipulated larger CB
unit. Patients had significantly more rapid neutrophil
and platelet engraftment and higher cumulative inci-
dence of neutrophil and platelet engraftment when com-
pared to a matched historical control group [39]. The
expanded cord predominated early post-HCT, while the
Stenger et al. BMC Immunology  (2015) 16:74 Page 7 of 10
unmanipulated cord predominated long-term (>1 year).
The authors attribute this observation to co-culture in-
creasing progenitor cells committed to megakaryocyte
and myeloid lineages and depleting cells important in
long-term repopulation [39].
Safety of MSCs in HCT
Numerous studies in a variety of conditions have thus
far documented safety following infusion of MSCs, and a
recent meta-analysis of 36 studies (including 11 HCT
studies) demonstrated no association with acute infusion
toxicity, organ toxicity, malignancy, infection or death
with a significant association only with transient fever
[40]. Based upon the immunosuppressive properties of
MSCs, downstream effects on malignant cells and infec-
tions have been of particular concern in HCT patients.
The previously described study by Ning et al. [38] is the
only published study reporting an increase in relapse
rate following MSC infusion, although as discussed, the
study did not report statistical analyses and did not pre-
serve the randomization. The inverse relationship found
between GVHD and relapse in this study, however, does
fit with numerous other studies documenting the same
effect (likely due to decreased graft-versus-leukemia ef-
fect, GVL) and warrants continued long-term monitor-
ing in patients receiving MSCs in the malignant setting.
Increased rates of infectious complications have been
reported in several small non-randomized trials, but as
previously stated no association was found in a recent
meta-analysis [40]. CMV viral loads and the rate of
CMV disease were higher than expected in thirty-one
patients receiving MSCs as treatment for GVHD or
hemorrhagic cystitis. All cases of CMV disease, however,
occurred in a GVHD-affected organ and most were de-
scribed as mild [41]. Further, this study was single arm
without even a historical comparison group reported, so
it is difficult to ascribe causative effect. A cohort of
pediatric patients receiving MSCs as treatment for
steroid-refractory GVHD had comparable rates of CMV,
EBV and adenovirus when compared to historical con-
trols, although adenoviral infection resulted in decreased
survival, particularly when it occurred following MSC
infusion [42]. While an effect on adenovirus-specific T
cells was found in vitro, no in vivo effect was found, and
the authors note significantly higher rates of HLA mis-
matched grafts in the MSC group [42]. Finally, a recent
retrospective analysis of 1021 patients transplanted at
the Karolinska University Hospital found MSC infusion
to be a significant predictor of post-transplant lympho-
proliferative disease on multivariate analysis, a finding
that has not been previously reported [43]. As none of
these studies were randomized trials, they serve as fur-
ther reminders that long-term monitoring in patients
receiving MSCs is necessary, particularly in future ran-
domized trials.
Conclusions
Future Directions for MSCs in HCT Setting
As shown in Table 3, clinical trials of MSCs have been
very heterogeneous in terms of HSC source, MSC
source, and MSC culture conditions. Although MSCs
have been described as immunoprivileged, pre-clinical
studies suggest that MSC donor source and culture con-
ditions alter their immunoregulatory potential. MSCs
upregulate MHC class I and express MHC class II under
inflammatory conditions, and MHC-mismatched murine
MSCs undergo specific immune-mediated rejection [44].
In a non-myeloablative experimental setting, donor
MSCs stimulate immune-mediated graft rejection
whereas host MSCs promote engraftment [14]. Third-
party MSCs, which have been the largest source in clin-
ical trials, showed no response, which the authors
hypothesize was secondary to their rejection [14]. Pre-
clinical studies reveal that MSC donor source may not
be as important in severely immunocompromised recipi-
ents, including NOD/SCID mice, fetal sheep, or in the
setting of significant conditioning (e.g. TBI) [13, 15, 16,
21, 23–25, 45]. These data indicate that donor source of
MSCs may be most critical in the setting of sublethal or
minimal conditioning, such as that often used in the
NMD setting. Culturing in FBS may also enhance MSC
immunogenicity [46]. The majority of clinical trials have
also used cryopreserved, serially expanded MSCs.
Freshly thawed MSCs have impaired in vitro T cell sup-
pression secondary to a reversible heat shock response
with diminished IFN-γ-dependent IDO up-regulation
[47]. Serial expansion of MSCs results in clonal impover-
ishment, telomere shortening and increased cell senes-
cence, and MSC passage correlates with response and
survival from acute GVHD suggesting a relationship
with functional impairment [41, 46].
The majority of pre-clinical studies have demonstrated
that MSCs can potentiate HSC engraftment, while clinical
trials have been difficult to interpret broadly due to being
small, largely non-randomized trials. These studies have
furthered evidence of safety in HCT populations and give
suggestion for potential impact of MSCs on engraftment,
particularly following haploidentical transplant [37]. Dif-
ferences in clinical efficacy may relate to the mechanisms
of graft failure in different donor settings- HSC homing or
cell number is likely more important in CBT, whereas
graft failure following haploidentical transplant is predom-
inantly immune-mediated [48]. This suggests that MSCs
could be particularly efficacious in promoting engraftment
of haploidentical HSCs. Pre-clinical studies also suggest
that MSCs have a greater impact on engraftment at lower
HSC doses, therefore may have greater impact in this
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clinical setting [15, 21]. Clinical trials to date also support
future studies of MSCs to prevent GVHD, with a signifi-
cant decrease in aGVHD reported in one study and no
aGVHD reported in two additional studies [31, 33, 37].
MSCs may have greater potential to impact on GVHD
when the inflammatory state is lower. The use of MSCs to
prevent GVHD may therefore be more successful than its
use to treat active GVHD. Finally, caution is indicated
when MSCs are given in a malignant disease setting, both
due to the potential for increased rates of relapse [38] and
to the known inverse ratio between relapse and GVHD/
GVL, suggesting that MSCs may be more safe and more
useful in the NMD setting. Regardless of the specific clin-
ical setting chosen, sufficient evidence of safety and early
evidence of efficacy exists regarding MSCs to facilitate
HSC engraftment and to prevent GVHD, warranting the
completion of larger, more homogenous, and ultimately,
randomized clinical trials. Additional pre-clinical studies
of MSCs, particularly in more immunocompetent rodents
and in large animal models, are still warranted to further
establish the ideal source of MSCs (and HSCs) and MSC
mechanism of action, particularly in potentiating
engraftment.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EOS drafted the manuscript and LK and JG revised the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the CHOA Center for Transplantation and
Immune-mediated Disorders Pilot Grant (EOS), ACTSI KL2-Mentored Clinical
and Translational Research Program (EOS), and the National Institutes of
Health grant KL2TR000455 (EOS).
Author details
1Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta,
Emory University, 1405 Clifton Road, Atlanta, GA 30322, USA. 2Department of
Hematology and Medical Oncology, Winship Cancer Institute, Emory
University, 1365 Clifton Road, Atlanta, GA 30322, USA.
Received: 18 June 2015 Accepted: 19 November 2015
References
1. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the
innate immune system. Nat Rev Immunol. 2012;12(5):383–96.
2. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone
marrow mesenchymal stem cells inhibit the response of naive and memory
antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722–9.
3. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood. 2005;105(4):1815–22.
4. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al.
Human mesenchymal stem cells alter antigen-presenting cell maturation
and induce T-cell unresponsiveness. Blood. 2005;105(5):2214–9.
5. Francois M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression
correlates with cytokine induction of indoleamine 2,3-dioxygenase and
bystander M2 macrophage differentiation. Molecular therapy : the journal of
the American Society of Gene Therapy. 2012;20(1):187–95.
6. Su J, Chen X, Huang Y, Li W, Li J, Cao K, et al. Phylogenetic distinction of iNOS
and IDO function in mesenchymal stem cell-mediated immunosuppression in
mammalian species. Cell Death Differ. 2014;21(3):388–96.
7. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
et al. Minimal criteria for defining multipotent mesenchymal stromal cells.
The International Society for Cellular Therapy position statement.
Cytotherapy. 2006;8(4):315–7.
8. Sensebe L, Bourin P, Tarte K. Good manufacturing practices production of
mesenchymal stem/stromal cells. Hum Gene Ther. 2011;22(1):19–26.
9. Baron F, Storb R. Mesenchymal stromal cells: a new tool against graft-
versus-host disease? Biology of blood and marrow transplantation :
journal of the American Society for Blood and Marrow Transplantation.
2012;18(6):822–40.
10. Kebriaei P, Robinson S. Treatment of graft-versus-host-disease with
mesenchymal stromal cells. Cytotherapy. 2011;13(3):262–8.
11. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone
marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-
dioxygenase-mediated tryptophan degradation. Blood. 2004;103(12):4619–21.
12. Chinnadurai R, Copland IB, Patel SR, Galipeau J. IDO-independent
suppression of T cell effector function by IFN-gamma-licensed human
mesenchymal stromal cells. J Immunol. 2014;192(4):1491–501.
13. Hiwase SD, Dyson PG, To LB, Lewis ID. Cotransplantation of placental
mesenchymal stromal cells enhances single and double cord blood
engraftment in nonobese diabetic/severe combined immune deficient
mice. Stem Cells. 2009;27(9):2293–300.
14. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE.
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic
host and stimulate donor graft rejection in a nonmyeloablative setting.
Blood. 2006;108(6):2114–20.
15. Angelopoulou M, Novelli E, Grove JE, Rinder HM, Civin C, Cheng L, et al.
Cotransplantation of human mesenchymal stem cells enhances human
myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol.
2003;31(5):413–20.
16. Almeida-Porada G, Porada CD, Tran N, Zanjani ED. Cotransplantation of human
stromal cell progenitors into preimmune fetal sheep results in early appearance
of human donor cells in circulation and boosts cell levels in bone marrow at later
time points after transplantation. Blood. 2000;95(11):3620–7.
17. Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J,
et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone
Marrow Transplant. 2013;48(4):537–43.
18. Mattsson J, Ringden O, Storb R. Graft Failure after Allogeneic Hematopoietic
Cell Transplantation. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplantation. 2008;
14(Supplement 1):165–70.
19. Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S,
et al. Unrelated donor cord blood transplantation for children with severe
sickle cell disease: results of one cohort from the phase II study from the
Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biology of
blood and marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation. 2012;18(8):1265–72.
20. Liu HL, Sun ZM, Geng LQ, Wang XB, Ding KY, Tang BI, et al. Unrelated cord
blood transplantation for newly diagnosed patients with severe acquired
aplastic anemia using a reduced-intensity conditioning: high graft rejection,
but good survival. Bone Marrow Transplant. 2012;47(9):1186–90.
21. Noort WA, Kruisselbrink AB, In’t Anker PS, Kruger M, Van Bezooijen RL, De
Paus RA, et al. Mesenchymal stem cells promote engraftment of human
umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol.
2002;30(8):870–8.
22. Anker PS ’t, Noort WA, Kruisselbrink AB, Scherjon SA, Beekhuizen W,
Willemze R, et al. Nonexpanded primary lung and bone marrow-derived
mesenchymal cells promote the engraftment of umbilical cord blood-
derived CD34(+) cells in NOD/SCID mice. Exp Hematol. 2003;31(10):881–9.
23. Kim DW, Chung YJ, Kim TG, Kim YL, Oh IH. Cotransplantation of third-
party mesenchymal stromal cells can alleviate single-donor predominance
and increase engraftment from double cord transplantation. Blood. 2004;
103(5):1941–8.
24. Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huenecke S, et al. CD271
antigen defines a subset of multipotent stromal cells with
immunosuppressive and lymphohematopoietic engraftment-promoting
properties. Haematologica. 2010;95(4):651–9.
25. Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L,
et al. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal
stem cells into the NOD/SCID mouse and their role in supporting human
CD34 cell engraftment. Blood. 2004;103(9):3313–9.
Stenger et al. BMC Immunology  (2015) 16:74 Page 9 of 10
26. Mielcarek M, Storb R, Georges GE, Golubev L, Nikitine A, Hwang B,
et al. Mesenchymal stromal cells fail to prevent acute graft-versus-host
disease and graft rejection after dog leukocyte antigen-haploidentical
bone marrow transplantation. Biology of blood and marrow
transplantation : journal of the American Society for Blood and Marrow
Transplantation. 2011;17(2):214–25.
27. Lee WS, Suzuki Y, Graves SS, Iwata M, Venkataraman GM, Mielcarek M, et al.
Canine bone marrow-derived mesenchymal stromal cells suppress
alloreactive lymphocyte proliferation in vitro but fail to enhance
engraftment in canine bone marrow transplantation. Biology of blood and
marrow transplantation : journal of the American Society for Blood and
Marrow Transplantation. 2011;17(4):465–75.
28. Masuda S, Ageyama N, Shibata H, Obara Y, Ikeda T, Takeuchi K, et al.
Cotransplantation with MSCs improves engraftment of HSCs after
autologous intra-bone marrow transplantation in nonhuman primates. Exp
Hematol. 2009;37(10):1250–7. e1251.
29. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI,
et al. Rapid hematopoietic recovery after coinfusion of autologous-blood
stem cells and culture-expanded marrow mesenchymal stem cells in
advanced breast cancer patients receiving high-dose chemotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical
Oncology. 2000;18(2):307–16.
30. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo
culture-expanded parental haploidentical mesenchymal stem cells to
promote engraftment in pediatric recipients of unrelated donor umbilical
cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant.
2009;43(6):447–54.
31. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, et al.
Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening
acute GVHD, but does not reduce the risk of graft failure in pediatric
patients undergoing allogeneic umbilical cord blood transplantation. Bone
Marrow Transplant. 2011;46(2):200–7.
32. Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb Jr LS,
et al. Unrelated donor allogeneic hematopoietic stem cell transplantation
for patients with hemoglobinopathies using a reduced-intensity
conditioning regimen and third-party mesenchymal stromal cells. Biology of
blood and marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation. 2014;20(4):581–6.
33. Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, Rico MA, Bautista G, Krsnik
I, et al. Results of a pilot study on the use of third-party donor
mesenchymal stromal cells in cord blood transplantation in adults.
Cytotherapy. 2009;11(3):278–88.
34. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B,
Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance
engraftment of hematopoietic stem cells. Leukemia. 2007;21(8):1733–8.
35. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al.
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal
stem cells and hematopoietic stem cells in hematologic malignancy
patients. Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation. 2005;11(5):389–98.
36. Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A, et al.
Infusion of mesenchymal stromal cells can aid hematopoietic recovery
following allogeneic hematopoietic stem cell myeloablative transplant: a
pilot study. Stem Cells Dev. 2009;18(9):1247–52.
37. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, et al.
Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates
lymphocyte recovery and may reduce the risk of graft failure in haploidentical
hematopoietic stem-cell transplantation. Blood. 2007;110(7):2764–7.
38. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, et al. The correlation
between cotransplantation of mesenchymal stem cells and higher
recurrence rate in hematologic malignancy patients: outcome of a pilot
clinical study. Leukemia. 2008;22(3):593–9.
39. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, et al.
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J
Med. 2012;367(24):2305–15.
40. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC,
et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a
systematic review and meta-analysis of clinical trials. PLoS One. 2012;
7(10):e47559.
41. von Bahr L, Sundberg B, Lonnies L, Sander B, Karbach H, Hagglund H, et al.
Long-term complications, immunologic effects, and role of passage for
outcome in mesenchymal stromal cell therapy. Biology of blood and
marrow transplantation : journal of the American Society for Blood and
Marrow Transplantation. 2012;18(4):557–64.
42. Calkoen FG, Vervat C, van Halteren AG, Welters MJ, Veltrop-Duits LA,
Lankester AC, et al. Mesenchymal stromal cell therapy is associated with
increased adenovirus-associated but not cytomegalovirus-associated
mortality in children with severe acute graft-versus-host disease. Stem cells
translational medicine. 2014;3(8):899–910.
43. Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al. Risk
factors for Epstein-Barr virus-related post-transplant lymphoproliferative
disease after allogeneic hematopoietic stem cell transplantation.
Haematologica. 2014;99(2):346–52.
44. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow
stromal cells are immune rejected by MHC class I- and class II-mismatched
recipient mice. Blood. 2005;106(13):4057–65.
45. In’t Anker PS, Noort WA, Scherjon SA, Kleijburg-van Der Keur C, Kruisselbrink
AB, Van Bezooijen RL, et al. Mesenchymal stem cells in human second-
trimester bone marrow, liver, lung, and spleen exhibit a similar
immunophenotype but a heterogeneous multilineage differentiation
potential. Haematologica. 2003;88(8):845–52.
46. Galipeau J. The mesenchymal stromal cells dilemma–does a negative phase
III trial of random donor mesenchymal stromal cells in steroid-resistant
graft-versus-host disease represent a death knell or a bump in the road?
Cytotherapy. 2013;15(1):2–8.
47. Francois M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J.
Cryopreserved mesenchymal stromal cells display impaired
immunosuppressive properties as a result of heat-shock response and
impaired interferon-gamma licensing. Cytotherapy. 2012;14(2):147–52.
48. Bernardo ME, Cometa AM, Locatelli F. Mesenchymal stromal cells: a novel
and effective strategy for facilitating engraftment and accelerating
hematopoietic recovery after transplantation? Bone Marrow Transplant.
2012;47(3):323–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Stenger et al. BMC Immunology  (2015) 16:74 Page 10 of 10
